New diabetes therapy
Through research, scientists have discovered a new type of insulin "accelerator."
When we eat, the body's insulin level will rise, it will send a signal to promote the absorption of circulating glucose by skeletal muscle.In the body of diabetic patients, this process is often damaged, which is called insulin resistance.
Insulin must pass through the inner wall of endothelial cells or small blood vessels to reach skeletal muscle, while inducing skeletal muscle glucose uptake.
Nitric oxide (NO) is a key regulator of endothelial cell function, which stimulates arterial vasodilation and increases the available surface area for insulin exchange.
The researchers find that when a compound called L-NAME blocks the function of nitric oxide synthase to reduce the level of nitric oxide in the mouse, the activity of insulin through endothelial cells is increased, as is the decrease in blood glucose caused by insulin stimulation.
The researchers concluded that the emergency pharmacological inhibition of nitric oxide synthase increases the permeability of capillaries to insulin and increases the action of insulin, thereby offsetting the acute effects of other organisms and reducing blood flow to capillaries. This could reveal a new mechanism for treating insulin resistance and help researchers develop new treatments for diabetics at a later stage.
In recent years, scientists have done a lot of research on Insulin. Our DLdevelop has developed a varity of Insulin Elisa kits such as DL-IGF1-Hu(Human Insulin Like Growth Factor 1 ELISA Kit) and DL-IGF1-Mu(Mouse Insulin Like Growth Factor 1 ELISA Kit). To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-igf1-hu.html
https://dldevelop.com/Research-reagent/dl-igf1-mu.html
When we eat, the body's insulin level will rise, it will send a signal to promote the absorption of circulating glucose by skeletal muscle.In the body of diabetic patients, this process is often damaged, which is called insulin resistance.
Insulin must pass through the inner wall of endothelial cells or small blood vessels to reach skeletal muscle, while inducing skeletal muscle glucose uptake.
Nitric oxide (NO) is a key regulator of endothelial cell function, which stimulates arterial vasodilation and increases the available surface area for insulin exchange.
The researchers find that when a compound called L-NAME blocks the function of nitric oxide synthase to reduce the level of nitric oxide in the mouse, the activity of insulin through endothelial cells is increased, as is the decrease in blood glucose caused by insulin stimulation.
The researchers concluded that the emergency pharmacological inhibition of nitric oxide synthase increases the permeability of capillaries to insulin and increases the action of insulin, thereby offsetting the acute effects of other organisms and reducing blood flow to capillaries. This could reveal a new mechanism for treating insulin resistance and help researchers develop new treatments for diabetics at a later stage.
In recent years, scientists have done a lot of research on Insulin. Our DLdevelop has developed a varity of Insulin Elisa kits such as DL-IGF1-Hu(Human Insulin Like Growth Factor 1 ELISA Kit) and DL-IGF1-Mu(Mouse Insulin Like Growth Factor 1 ELISA Kit). To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-igf1-hu.html
https://dldevelop.com/Research-reagent/dl-igf1-mu.html
